RCM
BBNX

RA Capital Management’s Beta Bionics BBNX Stock Holding History

RA Capital Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500,000
Closed -$7.28M – 76
2025
Q2 		$7.28M Hold
500,000
– – 0.12% 52
2025
Q1 		$6.12M Buy
+500,000
New +$9.32M 0.1% 73

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

RA Capital Management's BBNX Position: Q3 2025 in Review

RA Capital Management sold out of Beta Bionics (BBNX) in Q3 2025, closing a stake of 500,000 shares — an estimated $7.28M sold.

RA Capital Management first reported a position in BBNX in Q1 2025 and held it in 2 quarters. The position peaked at $7.28M in Q2 2025. 129 funds tracked by Wall St. Rank hold BBNX as of Q3 2025.

  • RA Capital Management reported no remaining Beta Bionics position as of Q3 2025 after selling out during the quarter.
  • RA Capital Management sold 500,000 Beta Bionics shares in Q3 2025, an estimated $7.28M.
  • RA Capital Management first reported a position in Beta Bionics in Q1 2025 and held it in 2 quarters.
  • RA Capital Management's Beta Bionics position peaked at $7.28M in Q2 2025.
  • 129 funds tracked by Wall St. Rank held Beta Bionics as of Q3 2025.

Based on RA Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.